Skip to content
Biodatica
Start free

Epizyme, Inc.

Duarte, California

OncologyPhase III
Compare Sign in to watch

What changed

Study registered, no phase assigned: Tazemetostat Expanded Access Program for Adults With Epithelioid Sarcoma

2w agoTrial registeredJul 2, 2026Source filing (opens the source filing in a new tab)

Momentum

90no change

Momentum 90 out of 100, unchanged since the last recompute.

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase III

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Peer position

491 pre-ticker oncology companies at Phase III

Peer ranking — where this company sits among its stage-and-area peers by momentum, and how its runway compares to the peer median — is part of the Analyst tier.

Compare seats

A ranking of the same momentum figure the feed publishes, computed live against public-filing peers. It is a relative position, not a recommendation, and it is identical for every viewer.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    Study registered

    Jul 2, 2026

    Epithelioid Sarcoma · NO_LONGER_AVAILABLE · sponsor: Epizyme, Inc. · Tazemetostat Expanded Access Program for Adults With Epithelioid Sarcoma

    ClinicalTrials.gov · NCT04225429 (opens the source filing in a new tab)

  2. Trial

    Study registered

    Jul 2, 2026

    Epithelioid Sarcoma (Ex-US Only), Spindle Cell Sarcoma, Sinonasal Carcinoma, Small Cell Carcinoma of the Ovary Hypercalcemic Type, Thoracic Sarcoma, Poorly Differentiated Chordoma, ATRT, Malignant Rhabdoid Tumor of Kidney, Malignant Rhabdoid Tumor of Ovary, Malignant Rhabdoid Tumor, Myxoid Spindle Cell Sarcoma, Epithelioid Malignant Peripheral Nerve Sheath Tumor, Chondrosarcoma, Renal Cell Carcinoma, Myoepithelial Carcinoma, Synovial Sarcoma, Renal Medullary Carcinoma, Malignant Mesothelioma, Desmoplastic Small Round Cell Tumor (DSRCT), Intramedullary Spinal Cord Schwannomatosis · NO_LONGER_AVAILABLE · sponsor: Epizyme, Inc. · Tazemetostat Expanded Access Program for Adults With Solid Tumors

    ClinicalTrials.gov · NCT03874455 (opens the source filing in a new tab)

  3. Trial

    PHASE2 registered

    Sep 2, 2025

    Follicular Lymphoma, Refractory Follicular Lymphoma · WITHDRAWN · sponsor: Epizyme, Inc. · A Study to Assess Efficacy and Safety of Oral Tazemetostat in Adult Participants With Relapsed/Refractory Follicular Lymphoma That Does Not Have an "EZH2 Gain-of-function" Genetic Mutation

    ClinicalTrials.gov · NCT06068881 (opens the source filing in a new tab)

  4. Trial

    PHASE1 registered

    May 31, 2022

    Multiple Myeloma, Refractory, Diffuse Large B-Cell Lymphoma, Diffuse Large B Cell Lymphoma Refractory, Multiple Myeloma in Relapse · TERMINATED · sponsor: Epizyme, Inc. · A Study of the Safety, Tolerability and Effectiveness of EZM0414 (IPN60210) Investigative Product in Participants With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B Cell Lymphoma

    ClinicalTrials.gov · NCT05121103 (opens the source filing in a new tab)

  5. Trial

    PHASE3 registered

    Jun 11, 2020

    Relapsed/Refractory Follicular Lymphoma, Follicular Lymphoma, Refractory Follicular Lymphoma · ACTIVE_NOT_RECRUITING · sponsor: Epizyme, Inc. · A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.

    ClinicalTrials.gov · NCT04224493 (opens the source filing in a new tab)

  6. Trial

    PHASE1 registered

    Dec 19, 2019

    Advanced Soft-tissue Sarcoma, Advanced Epithelioid Sarcoma · TERMINATED · sponsor: Epizyme, Inc. · Tazemetostat in Combination With Doxorubicin as Frontline Therapy for Advanced Epithelioid Sarcoma

    ClinicalTrials.gov · NCT04204941 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources